Network meta-analysis on the efficacy and safety of finerenone versus SGLT2 inhibitors on reducing new-onset of atrial fibrillation in patients with type 2 diabetes mellitus and chronic kidney disease.
Network meta-analysis on the efficacy and safety of finerenone versus SGLT2 inhibitors on reducing new-onset of atrial fibrillation in patients with type 2 diabetes mellitus and chronic kidney disease.
复制标题
DOI：
10.1186/s13098-022-00929-3
复制
发表时间：
2022-10-27
影响因子：
4.8
通讯作者：
中科院分区：
文献类型：
--
作者：
评价芬尼酮和钠-葡萄糖共转运蛋白-2抑制剂（SGLT2i）降低2型糖尿病（T2DM）合并慢性肾病（CKD）患者新发房颤（AF）的疗效和安全性。我们检索了PubMed， Cochrane Library, Web of Science， Medline和Embase，涵盖2000年1月1日至2022年4月30日。选择比较芬尼酮或SGLT2i与安慰剂在T2DM和CKD患者中的随机对照试验。结果以风险比（RR）和相应的95%置信区间（CI）报告。共纳入10项研究（35,841例患者）。与安慰剂相比，芬纳酮（RR 0.79, 95% CI 0.62-0.99）与房颤风险降低相关，而SGLT2i则与之无关。与细芬烯酮相比，SGLT2i与心力衰竭住院风险降低相关（RR 0.78, 95% CI 0.63-0.98）。他们在房事（RR 0.84, 95% CI 0.48,1.46）、主要不良心血管事件（MACE） （RR 0.93, 95% CI 0.81,1.06）和非致死性卒中（RR 0.78, 95% CI 0.58,1.05）方面具有可比性。与安慰剂相比，他们都没有明显的不良事件风险。根据现有临床研究的间接比较，芬尼酮和SGLT2i在减少新发房颤方面没有显著差异。为了得到更精确的结论，需要进行大样本的面对面试验。在线版本包含补充资料，下载地址：10.1186/s13098-022-00929-3。
To evaluate the efficacy and safety of finerenone and sodium-glucose cotransporter-2 inhibitors (SGLT2i) on reducing new-onset of atrial fibrillation (AF) in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD). We searched the PubMed, Cochrane Library, Web of Science, Medline and Embase covering January 1, 2000 to April 30, 2022. Randomized control trials comparing finerenone or SGLT2i with placebo in patients with T2DM and CKD were selected. Results were reported as risk ratio (RR) with corresponding 95% confidence interval (CI). A total of 10 studies (35,841 patients) were included. Finerenone (RR 0.79, 95% CI 0.62–0.99) was associated with a decreased risk of AF compared with placebo, while SGLT2i were not. SGLT2i were associated with a decreased risk of hospitalization for heart failure (RR 0.78, 95% CI 0.63–0.98) compared with finerenone. They were comparable in AF(RR 0.84, 95% CI 0.48,1.46), major adverse cardiovascular events(MACE) (RR 0.93, 95% CI 0.81,1.06) and nonfatal stroke(RR 0.78, 95% CI 0.58,1.05). They both showed no significant risk of adverse events compared with placebo. There was no significant difference in the reduction of new-onset of atrial fibrillation between Finerenone and SGLT2i based on the indirect comparisons of currently available clinical studies. The large-sampled head-to-head trials was needed for the more precise conclusion. The online version contains supplementary material available at 10.1186/s13098-022-00929-3.
登录
查看更多内容
影响因子：
16.2
作者：
通讯作者：
--
影响因子：
39.2
作者：
Hutton, Brian;Salanti, Georgia;Moher, David
通讯作者：
Moher, David
影响因子：
4.8
作者：
Lavall, Daniel;Schuster, Pia;Laufs, Ulrich
通讯作者：
Laufs, Ulrich
DOI：
10.1007/164_2016_76
发表时间：
2017-01-01
期刊：
HEART FAILURE
影响因子：
--
作者：
Kolkhof, Peter;Jaisser, Frederic;Pitt, Bertram
通讯作者：
Pitt, Bertram
影响因子：
44.5
作者：
Barnett, Anthony H.;Mithal, Ambrish;Broedl, Uli C.
通讯作者：
Broedl, Uli C.